Dyne Therapeutics (DYN) Operating Expenses (2019 - 2026)

Dyne Therapeutics' Operating Expenses history runs 8 years deep, the most recent figure standing at $125.3 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 2.37% year-over-year to $125.3 million; the TTM figure through Mar 2026 stood at $471.1 million (up 18.63% YoY), while the FY2025 annual figure was $468.2 million, up 36.15% from the prior year.
• Operating Expenses was $125.3 million for Q1 2026 at Dyne Therapeutics, up from $116.1 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $125.3 million in Q1 2026 to a low of $35.8 million in Q1 2022.
• Historically, Operating Expenses has averaged $79.4 million across 5 years, with a median of $69.2 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses decreased 22.74% in 2022, then jumped 76.95% in 2025.
• A 5-year view of Operating Expenses shows it stood at $40.1 million in 2022, then surged by 68.61% to $67.7 million in 2023, then surged by 43.46% to $97.1 million in 2024, then advanced by 19.59% to $116.1 million in 2025, then increased by 7.88% to $125.3 million in 2026.
• The last three Operating Expenses figures came in at $125.3 million (Q1 2026), $116.1 million (Q4 2025), and $113.9 million (Q3 2025), per Business Quant data.